Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times. During the first half of 2026 and 2025, the Company had three major raw material suppliers that collectively accounted for approximately 83% and 85%, respectively, of the raw material purchases made by the Company. For the three months ended June 30, 2026 and 2025, the Company had three major raw material suppliers that collectively accounted for approximately 83% and 92%, respectively, of the raw material purchases made by the Company. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.